Finally, third-generation CAR-T cells targeting MUC1 but also multiple other targets (PSCA, TGFβ, HER2, Mesothelin, LeY, GPC3, AXL, EGFR, Claudin18.2, or B7-H3) were constructed, and clinical studies will be performed to test the anticancer function of these individual or combination CAR-T cells for immunotherapy in human cancer. The gene discussed is MUC1; the disease is cancer.